about
Aldosterone antagonists for preventing the progression of chronic kidney diseasePentoxifylline for Anemia in Chronic Kidney Disease: A Systematic Review and Meta-AnalysisNeutrophil gelatinase-associated lipocalin (NGAL): a new piece of the anemia puzzle?The erythropoietin and regenerative medicine: a lesson from fish.Biomarkers of cardio-renal damage in chronic kidney disease: one size cannot fit all.Antioxidant agents for delaying diabetic kidney disease progression: A systematic review and meta-analysis.Emerging markers of cachexia predict survival in cancer patients.Dietary restriction and exercise for diabetic patients with chronic kidney disease: a systematic review.Both IL-1β and TNF-α regulate NGAL expression in polymorphonuclear granulocytes of chronic hemodialysis patients.From the oxygen to the organ protection: erythropoietin as protagonist in internal medicine.Caffeine and the kidney: what evidence right now?Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease.Pregnancy in uremic patients: an eventful journey.Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage.Dialysis and the elderly: an underestimated problem.Preeclampsia and cardiovascular risk: general characteristics, counseling and follow-up.Arrhythmias and hemodialysis: role of potassium and new diagnostic tools.Malnutrition in the elderly patient on dialysis.Regenerative medicine: does Erythropoietin have a role?Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene.Endothelial progenitor cells: pathogenetic role and therapeutic perspectives.Renal complications in oncohematologic patients.Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment.From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology.Acute cardiovascular complications of hemodialysis.Vasopressin beyond water: implications for renal diseases.NGAL is a precocious marker of therapeutic response.A new therapy for kidney injury: regeneration.Glitazones in chronic kidney disease: potential and concerns.An overview of standard statistical methods for assessing exposure-outcome link in survival analysis (Part I): basic concepts.An overview on standard statistical methods for assessing exposure-outcome link in survival analysis (Part II): the Kaplan-Meier analysis and the Cox regression method.Pulmonary hypertension in CKD.Prognostic models in the clinical arena.Relaxin: new pathophysiological aspects and pharmacological perspectives for an old protein.The quality of reporting in clinical research: the CONSORT and STROBE initiatives.European Renal Best Practice (ERBP) Guideline development methodology: towards the best possible guidelines.Effects of weight loss on renal function in obese CKD patients: a systematic review.Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties.The aging kidney revisited: a systematic review.Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology.
P50
Q24194979-C5A2911A-94FD-4E10-B960-06B039927B43Q26799740-69D1B57F-56D1-46B5-8768-2A3CB62DACBAQ33349167-3FE0B4F9-8F4B-498C-B955-96B146F673B9Q33483623-9444E163-AB68-4CF4-8DAF-D698769CFDA6Q33750340-208491F4-5680-4B05-BC8F-66120E39CF2CQ33751985-5E9072EE-8098-45E5-8E2F-95E6F5C3FFB8Q34551579-156A23C6-1A77-46F3-98CA-DEED65C59F90Q34572119-22480028-EE48-42F6-9631-A904F64A1E17Q34635140-88EB7BCB-7E5E-4089-915C-F138ACFC145BQ36638524-D79D9C11-CF94-485F-B50A-72C04FC64D5FQ36857167-238F43FF-E92B-4250-8EAF-6201B9691D78Q37087937-31D4FFDC-71B8-4487-AC9E-F5591CE6CA92Q37138568-61BB516E-C97C-4E37-A015-368FB92BEAB4Q37251326-FCD8F2AC-9E75-4CFC-824F-6590EA4C51E9Q37303677-F0F156B0-AE06-488C-A748-D826AC3CCC92Q37307749-908CC4CE-9D9F-4BFF-B338-F01C1AA884DBQ37368059-51835B85-F2FB-421B-BF13-0C8114BC3822Q37415495-5B500089-53B3-4599-9E97-F1D78AC7F026Q37515923-EBF51B9F-8872-4FC3-BC07-B9144613D138Q37525013-F510E444-77EE-401C-9820-340517B736B2Q37575089-A3ED96F7-62FA-4A17-B8DE-33C7BABC7FD0Q37642548-862B6C3B-47F6-470C-BBBA-D9C787B45ED6Q37722237-E9C6B290-A18B-4343-8810-DEC6EEB51083Q37736542-43F544E1-2A29-42D1-B880-F2BF88E36D1BQ37737962-68EA4AF7-B8CD-4EE6-BF98-E54161A89F47Q37778262-AC18476A-66FF-406A-AD4D-60527148D119Q37849805-22EED106-7B43-453C-A8CD-2CD578709779Q37857179-5E73CB88-2D15-44EC-BA5D-83B4A900A75DQ37988060-CCAC602F-650A-4118-BB59-A1B011FE291DQ38030388-072604B3-43D4-461E-9B62-7DF17B7301F3Q38056818-68766857-5C5B-4F33-BB0A-1824EA13EA28Q38060950-508D7D97-8C9E-4808-9680-6ECA9459F647Q38067242-9AC3212D-65C4-4256-BC9D-1CDEEDBD9213Q38080804-046A1249-A8A0-4EF6-8362-03045EF76C44Q38112390-73F35FDD-89FC-4D9C-BB47-58D6376050C0Q38148074-27A2AAD7-6142-43E5-B2CC-495255515238Q38149111-03E6AA28-075C-4177-940B-7477ADA8B795Q38169915-E93CDCAC-D041-44C5-B9BA-F6B26E7F72AAQ38189218-540FCCA5-8189-42A4-A111-9431BC23225BQ38221154-BCBBB951-CF5C-4893-9927-25ACF3F05027
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Davide Bolignano
@ast
Davide Bolignano
@en
Davide Bolignano
@es
Davide Bolignano
@nl
Davide Bolignano
@sl
type
label
Davide Bolignano
@ast
Davide Bolignano
@en
Davide Bolignano
@es
Davide Bolignano
@nl
Davide Bolignano
@sl
prefLabel
Davide Bolignano
@ast
Davide Bolignano
@en
Davide Bolignano
@es
Davide Bolignano
@nl
Davide Bolignano
@sl
P106
P21
P31
P496
0000-0003-3032-245X